Telesis Bio, Inc. (DNAY) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET
Company Participants
Todd Nelson - CEO
Brent Hunter - VP, Finance
Conference Call Participants
Brandon Couillard - Jefferies
Operator
Welcome to the Q3 2022 Telesis Bio Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the call over to your speaker today, CEO, Todd Nelson. Please go ahead.
Todd Nelson
Thank you. Good afternoon, and thanks for joining us for Telesis Bio's Third Quarter 2022 Earnings Call. With me on the call today are Chief Operating Officer, Eric Esser; Dan Gibson, Co-Founder and CTO; and our VP of Finance, Brent Hunter. Our third quarter press release is available now on the Investors section of our website.
Before we begin, I'd like to inform you that certain statements we make during the call will be forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement included in our earnings release and in our filings with the SEC. This conference call contains time-sensitive information and is accurate only as of the live broadcast on November 8, 2022.
Finally, any percentage changes we discuss will be on a year-over-year basis unless otherwise noted. And with that, we can get started. Telesis Bio, our mission is to inspire and empower scientific breakers across life sciences translational research applications. Our automated on-demand multiomic and synthetic biology solutions enable scientists to streamline and standardize both building and testing of DNA and mRNA, allowing us to address large unmet needs in our targeted markets.
Our customers and collaborators include premier academic research institutions, rapidly growing biotech companies nearly all -- top 25 biopharma companies. Our systems are utilized by academic and industry sciences worldwide in various discovery activities ranging from the discovery of novel infectious disease vaccines, developing precision immunotherapies for cancer and antibody therapeutics to the creation of engineered need substitutes in sustainable cellular agricultural products.
Our biopsy automation solutions allow scientists to synthesize and assemble DNA and mRNA with the push of the button, allowing our customers to bring critical products to the market in an unprecedented amount of time. We believe that our strong financial momentum will support long-term issues of the company. And with that, I'll turn our discussion as -- we turn the discussion to recently reported financial results and corporate updates.